Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis

Purpose The aim of this study was to elucidate the rates and prognostic roles of programmed cell death ligand 1 (PD-L1) immunohistochemical (IHC) expression in various malignant tumors through a systematic review and meta-analysis. Method The current study included 16,176 patients from 97 eligible studies. We investigated PD-L1 expression and its correlation with survival rate in various malignant tumors. Results The estimated rate of PD-L1 IHC expression was 0.449 (95% confidence interval [CI] 0.404-0.495). The highest and lowest PD-L1 expression levels were found in thyroid cancer (0.829, 95% CI 0.781-0.868) and small-cell neuroendocrine carcinoma (0.005, 95% CI 0.000-0.080), respectively. PD-L1 expression was significantly correlated with poorer overall survival and disease-free survival rates (hazard ratios 1.276, 95% CI 1.097-1.486 and 1.304, 95% CI 1.034-1.644, respectively). However, PD-L1 IHC expression was significantly correlated with worse overall survival rates in patients with esophageal cancer and renal cell carcinoma and with worse disease-free survival rates in patients with colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma. Conclusions Our results show that PD-L1 expression rates and the correlations with survival varied between tumor types. Detailed evaluation criteria for PD-L1 will have to be standardized before application to specific tumor types.

[1]  A. Qattan,et al.  The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.

[2]  C. Blank,et al.  PD‐1 expression on Melan‐A‐reactive T cells increases during progression to metastatic disease , 2012, International journal of cancer.

[3]  Toby C. Cornish,et al.  Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma , 2016, Gut.

[4]  M. Mandalà,et al.  The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Jinming Yu,et al.  Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. , 2015, Translational research : the journal of laboratory and clinical medicine.

[6]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[7]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[8]  Rui Zhang,et al.  B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. , 2014, Acta histochemica.

[9]  H. Niu,et al.  Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[10]  R. Thompson,et al.  Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  Biao Xu,et al.  The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism , 2014, Medical Oncology.

[12]  M. Mandalà,et al.  PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Luciane T. Kagohara,et al.  PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival , 2013, Cancer Immunology Research.

[14]  N. Xu,et al.  Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. , 2006, Acta histochemica.

[15]  Shufeng Zhou,et al.  Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer , 2015, Drug design, development and therapy.

[16]  S. Dermime,et al.  FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy , 2008, BMC Cancer.

[17]  Y. Toiyama,et al.  Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy , 2016, International Journal of Clinical Oncology.

[18]  L. Sarian,et al.  Prognostic significance of PD-L1 and PD-L2 in breast cancer. , 2016, Human pathology.

[19]  G. Freeman,et al.  PD-L1 expression in nonclear-cell renal cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[21]  Jun Hu,et al.  PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer , 2013, PloS one.

[22]  Xuyou Zhu,et al.  Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. , 2015, International journal of clinical and experimental pathology.

[23]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[24]  Jing Sun,et al.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. , 2012, World journal of gastroenterology.

[25]  W. Dong,et al.  The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology. , 2015, European review for medical and pharmacological sciences.

[26]  L. Xue,et al.  Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. , 2016, Human pathology.

[27]  F. Gao,et al.  Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer , 2014, Breast Cancer Research and Treatment.

[28]  Koichiro Matsumoto,et al.  Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers , 2007, Cancer Immunology, Immunotherapy.

[29]  G. Mann,et al.  PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma , 2016, Clinical Cancer Research.

[30]  G. Freeman,et al.  Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  R. Assi,et al.  Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker? , 2016, Clinical genitourinary cancer.

[32]  Dajun Yang,et al.  Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. , 2015, International journal of clinical and experimental pathology.

[33]  Krishna R. Kalari,et al.  Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma , 2013, Cancer Immunology Research.

[34]  G. Brabant,et al.  Costimulatory Molecule B7-H1 in Primary and Metastatic Clear Cell Renal Cell Carcinoma , 2006 .

[35]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[36]  M. Srougi,et al.  PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis , 2015, Diagnostic Pathology.

[37]  K. Hirakawa,et al.  Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. , 2015, Anticancer research.

[38]  S. Nonogaki,et al.  Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. , 2013, Endocrine-related cancer.

[39]  Roman K. Thomas,et al.  PD-L1 expression in small cell neuroendocrine carcinomas. , 2015, European journal of cancer.

[40]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[41]  D. Hua,et al.  MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. , 2014, Human immunology.

[42]  Daniela Massi,et al.  PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. , 2016, Critical reviews in oncology/hematology.

[43]  Jingting Jiang,et al.  B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. , 2014, International journal of clinical and experimental pathology.

[44]  Jing‐ying Hou,et al.  Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. , 2014, Experimental and molecular pathology.

[45]  S. Boorjian,et al.  T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival , 2008, Clinical Cancer Research.

[46]  M. Shimada,et al.  Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection , 2016, Gastric Cancer.

[47]  A. Russo,et al.  PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis , 2016, Oncotarget.

[48]  H. Kalthoff,et al.  PD-L1 is an independent prognostic predictor in gastric cancer of Western patients , 2016, Oncotarget.

[49]  J. Madore,et al.  PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.